My Cart
You have no items in your shopping cart.
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
S614268-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $589.90 | |
S614268-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $825.90 | |
S614268-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,444.90 |
Synonyms | 5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide | DTXSID2047357 | UNII-SF8R9VCB0X | SR147778 | SR-147778 | Surinabant | Surinabant [INN] | SF8R9VCB0X | SR 147778 | CHEMBL189676 |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Cannabinoid CB1 receptor antagonist |
Product Description |
Surinabant, a cannabinoid CB1 antagonist, is used potentially for the treatment of obesity and alcoholism.
|
ALogP | 7 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|---|---|---|---|---|---|---|
Cannabinoid CB1 receptor agonist | AGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | DailyMed: [1] | |
Cannabinoid CB1 receptor agonist | AGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | ||
Cannabinoid CB1 receptor agonist | AGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | ||
Cannabinoid CB1 receptor antagonist | ANTAGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | PubMed: [1] | |
Cannabinoid CB1 receptor antagonist | ANTAGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | Other: [1] | |
Cannabinoid CB1 receptor antagonist | ANTAGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | ||
Cannabinoid CB1 receptor antagonist | ANTAGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | PubMed: [1] | |
Cannabinoid CB1 receptor agonist | AGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | ||
Cannabinoid CB1 receptor antagonist | ANTAGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | PubMed: [1] | |
Cannabinoid CB1 receptor inverse agonist | INVERSE AGONIST | ALA218 | Cannabinoid CB1 receptor | SINGLE PROTEIN | Homo sapiens | PubMed: [1] |
IUPAC Name | 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-piperidin-1-ylpyrazole-3-carboxamide |
---|---|
INCHI | InChI=1S/C23H23BrCl2N4O/c1-2-18-21(23(31)28-29-12-4-3-5-13-29)27-30(20-11-10-17(25)14-19(20)26)22(18)15-6-8-16(24)9-7-15/h6-11,14H,2-5,12-13H2,1H3,(H,28,31) |
InChi Key | HMXDWDSNPRNUKI-UHFFFAOYSA-N |
Canonical SMILES | CCc1c(nn(c1c1ccc(cc1)Br)c1ccc(cc1Cl)Cl)C(=O)NN1CCCCC1 |
Isomeric SMILES | CCC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Br |
PubChem CID | 9849616 |
Molecular Weight | 522.26 |
Find and download the COA for your product by matching the lot number on the packaging.
6 results found
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
J2421753 | Certificate of Analysis | Jul 19, 2024 | S614268 |
J2421754 | Certificate of Analysis | Jul 19, 2024 | S614268 |
J2421755 | Certificate of Analysis | Jul 19, 2024 | S614268 |
J2421756 | Certificate of Analysis | Jul 19, 2024 | S614268 |
J2421757 | Certificate of Analysis | Jul 19, 2024 | S614268 |
J2421758 | Certificate of Analysis | Jul 19, 2024 | S614268 |
1. Janero DR, Makriyannis A. (2009) Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.. Expert Opin Emerg Drugs, 14 (1): (43-65). [PMID:19249987] [10.1021/op500134e] |
2. Lallemand F, De Witte P. (2006) SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats.. Alcohol, 39 (3): (125-34). [PMID:17127132] [10.1021/op500134e] |
3. Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Pério A, Poncelet M, Maruani J, Arnone M, Finance O et al.. (2004) SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.. J Pharmacol Exp Ther, 310 (3): (905-14). [PMID:15131245] [10.1021/op500134e] |